- Home
- SPRB vs GTBP Comparison
SPRB vs GTBP Comparison
Compare SPRB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRB
- GTBP
- Stock Information
- Founded
- SPRB 2014
- GTBP 1965
- Country
- SPRB United States
- GTBP United States
- Employees
- SPRB N/A
- GTBP N/A
- Industry
- SPRB Medicinal Chemicals and Botanical Products
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- SPRB Health Care
- GTBP Health Care
- Exchange
- SPRB Nasdaq
- GTBP Nasdaq
- Market Cap
- SPRB 5.5M
- GTBP 5.5M
- IPO Year
- SPRB 2020
- GTBP N/A
- Fundamental
- Price
- SPRB $0.13
- GTBP $2.28
- Analyst Decision
- SPRB Hold
- GTBP Strong Buy
- Analyst Count
- SPRB 5
- GTBP 1
- Target Price
- SPRB $1.75
- GTBP $11.00
- AVG Volume (30 Days)
- SPRB 2.6M
- GTBP 14.8K
- Earning Date
- SPRB 04-15-2025
- GTBP 05-14-2025
- Dividend Yield
- SPRB N/A
- GTBP N/A
- EPS Growth
- SPRB N/A
- GTBP N/A
- EPS
- SPRB N/A
- GTBP N/A
- Revenue
- SPRB $4,911,000.00
- GTBP N/A
- Revenue This Year
- SPRB N/A
- GTBP N/A
- Revenue Next Year
- SPRB $312.50
- GTBP N/A
- P/E Ratio
- SPRB N/A
- GTBP N/A
- Revenue Growth
- SPRB N/A
- GTBP N/A
- 52 Week Low
- SPRB $0.12
- GTBP $1.72
- 52 Week High
- SPRB $0.87
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- SPRB 23.23
- GTBP 48.56
- Support Level
- SPRB $0.11
- GTBP $2.15
- Resistance Level
- SPRB $0.14
- GTBP $2.38
- Average True Range (ATR)
- SPRB 0.03
- GTBP 0.17
- MACD
- SPRB -0.01
- GTBP -0.01
- Stochastic Oscillator
- SPRB 11.12
- GTBP 32.35
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.